EMA: Draft guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies

The scope of this document is to describe the basis and regulatory requirements for the use of minimal residue disease (MRD) as an intermediate endpoint to predict clinical benefit in trials in chronic lymphocytic leukaemia (CLL). At present, this guidance is not applicable to other clinical settings.